Deals ramp up in Asia’s healthcare space with cancer focus

There have been several high profile deals and developments in Asia’s cancer treatment space over the last few weeks, showing the growing interest a range of investors have in the region's healthcare sector. 

This includes a $1.5 billion investment from UK-Swedish pharmaceutical giant AstraZeneca in Singapore, a listing on the Hong Kong Stock Exchange HKEX by Chinese biopharmaceutical firm Sunho Biologics and an acquisition in Hong Kong by the New Frontier Group of the Hong Kong Integrated Oncology Center, a leading private oncology medical platform. 

Garri Zmudze, general partner at venture capital firm LongeVC, told FinanceAsia on...